Epiendo Pharmaceuticals

This phase 2 trial investigates the safety and tolerability of EP395, an oral capsule taken once daily for 12 weeks, in people with chronic obstructive pulmonary disease (COPD). The study includes 61 adults aged 45 and older and compares EP395 against a placebo. Researchers monit…

This early-stage trial tested whether EP395, an oral capsule, can reduce lung inflammation in healthy adults. All 49 participants inhaled a substance that causes temporary airway inflammation, mimicking a key feature of COPD. Researchers measured inflammation levels and collected…

This study looked at how a new medicine called EP395, being developed for COPD, interacts with other common drugs. It involved 37 healthy adults aged 18 to 55. The goal was to see if EP395 changes how other drugs work in the body, which helps doctors use it safely in the future.

This early-stage study tested the safety and tolerability of a new drug called EP395 in 78 healthy adults aged 18-65. Participants received either EP395 or a placebo capsule, and researchers monitored side effects, vital signs, and hearing. The goal was to find a safe dose range …

This early-stage trial tested an experimental drug called EP395 in 40 healthy adults. Researchers used a safe, temporary lung inflammation challenge to see how EP395 affects immune markers in the blood and lungs. The main goal was to gather safety data and understand the drug's e…